GloboMax was founded in 1997 by David Young, Pharm.D., Ph.D. and Keith Chan, Ph.D. with a commitment to help pharmaceutical and biotech companies successfully develop drug products for the world market, while simultaneously achieving distinguished excellence in pharmaceutical sciences and technology. In September 2003, GloboMax became a division of ICON plc joining forces with Icon's west coast based Early Phase International Consulting (EPIC) unit. Now as a business unit of ICON, GloboMax continues its focus in pharmaceutical development strategy, management and implementation, with division locations in San Francisco, Philadelphia, Baltimore and London. To become the world leader in providing the most effective scientific, regulatory, technology, and management solutions to accelerate pharmaceutical product development in true partnership with our clients.
This article uses content from
http://www.AboutUs.org
